The Munich-based medtech startup Kumovis has successfully completed its Series A financing round, raising €3.6 million. Investors include High-Tech Gründerfonds and Ffilipa Venture Capital, which already invested in the seed phase, as well as Renolit and Solvay Ventures.
Kumovis has developed a 3D printer with an integrated cleanroom environment specifically for medical technology. This printer produces, among other things, customized implants and is suitable for the series production of medical devices made of high-performance plastics. The focus is on processing high-performance polymers such as PEEK and PPSU, which are already established in medical technology and approved for the manufacture of medical devices. In 2019, the startup with the Kumovis R1, the latest model of its 3D printer. Miriam Haerst, Co-CEO and co-founder of Kumovis, explains:
"The flexibility of the Kumovis R1 system, which meets the requirements of medical manufacturing, is particularly beneficial for manufacturers dealing with small-batch and patient-specific products. By providing an open 3D printing system capable of processing a wide range of thermoplastic polymers, we enable our customers not only to manufacture medical products on demand, but also to 3D print them directly at the point of care. Now, we at Kumovis are excited to take the next steps together with our new and established partners."
Kumovis now aims to strengthen its business case and accelerate the company's sustainable development through these new partnerships. Renolit, a specialist in polymer-based components for medical devices, and Solvay, a global supplier of high-performance specialty polymers, bring the appropriate expertise to the table. Stefan Leonhardt, Co-CEO and co-founder of Kumovis, explains:
“We will use the investments to enter new markets, further develop our technology, and support the medical community in bringing 3D-printed medical devices to patients.”
Together with Kumovis “accelerating the transition to personalized medicine”
Stéphane Roussel, Managing Director of Solvay Ventures, says:
"The impressive team, as well as the product quality and performance characteristics, give us confidence that Kumovis is poised to fundamentally transform manufacturing in the demanding medical device industry. Kumovis and Solvay will work together to accelerate the transition to personalized medicine, expanding the scope of applications for high-performance specialty polymers in healthcare. Together, we have the potential to do the same in other industries."
Thomas Sampers, Head of Renolit Healthcare, adds:
“This investment is an important step for Renolit Healthcare to further its momentum toward healthcare innovation with partners and strengthen its presence in the medical device sector.”
